Lead Plaintiff Deadlines Set for CoreWeave, Inovio
Law firms are reminding investors of upcoming deadlines to file as lead plaintiff in securities fraud lawsuits. The deadline for purchasers of CoreWeave, Inc. securities is March 13, 2026, while the deadline for Inovio Pharmaceuticals, Inc. investors is April 7, 2026.
- The lawsuit against CoreWeave alleges the company made misleading statements about its capacity to meet customer demand and downplayed the risks of relying on a single third-party data center supplier. - The class period for the CoreWeave lawsuit covers investors who purchased securities between March 28, 2025, and December 15, 2025. - Allegations against CoreWeave intensified after a planned merger with digital infrastructure company Core Scientific was terminated on October 30, 2025, due to a lack of shareholder approval. - Following the failed merger and news of data center construction delays, CoreWeave's stock price saw significant drops, including a decline of over 16% on November 11, 2025. - The Inovio Pharmaceuticals lawsuit alleges the company made false and misleading statements concerning manufacturing for its CELLECTRA device. - The legal action against Inovio also claims the company was unlikely to submit its Biologics License Application for INO-3107 to the FDA by the second half of 2024 as publicly stated. - The class period for the Inovio lawsuit is for investors who purchased securities between October 10, 2023, and December 26, 2025. - This is not the first securities lawsuit Inovio has faced; a previous class action was filed concerning statements made between February and August 2020 regarding the company's COVID-19 vaccine candidate.
